Skip to NavigationSkip to content

Boehringer injects €230 million in new Biologicals Development Center

Published on 26/06/18 at 12:36pm

Prominent industry player Boehringer Ingelheim has unveiled plans to invest €230 million into the construction of a new Biologicals Development Center in Germany.

The investment is a bid to expand developmental capacity in order to facilitate growth in the company’s drug pipeline, which will in turn free up resources for contract manufacturing. The new site will focus development in areas of unmet medical need, featuring a combination of biologics analytical and process development, as well as manufacturing capacity for clinical studies.  

The new facility will be located alongside its existing Research and Development site in Biberach. It is expected to launch in staggered phases beginning in 2020 and will employ 500 staff. The company also has existing biopharmaceutical facilities in Austria, China, and the US.

“The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” commented Dr Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached 40%.”

Matt Fellows

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches